Clinical and economic value of screening for Kras mutations as predictors of response to epidermal g...
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
About this item
Full title
Author / Creator
Publisher
England: American Society of Health-System Pharmacists
Journal title
Language
English
Formats
Publication information
Publisher
England: American Society of Health-System Pharmacists
Subjects
More information
Scope and Contents
Contents
The clinical and economic value of screening for Kras mutations as predictors of response to cetuximab and panitumumab are reviewed.
Epidermal growth factor receptor (EGFR) inhibitors cetuximab and panitumumab are agents currently used in the treatment of metastatic colorectal cancer. Cetuximab is approved in combination with irinotecan for seco...
Alternative Titles
Full title
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracacademiconefile_A231808982
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A231808982
Other Identifiers
ISSN
1079-2082
E-ISSN
1535-2900
DOI
10.2146/ajhp090036
